| Primary |
| Acute Myeloid Leukaemia |
34.1% |
| Burkitt's Lymphoma |
27.4% |
| Prophylaxis |
9.1% |
| Acute Lymphocytic Leukaemia |
4.9% |
| Inflammatory Bowel Disease |
4.3% |
| Product Used For Unknown Indication |
4.3% |
| Crohn's Disease |
3.7% |
| Drug Use For Unknown Indication |
3.0% |
| Immunosuppression |
3.0% |
| Lymphocytic Leukaemia |
3.0% |
| B Precursor Type Acute Leukaemia |
0.6% |
| Colitis Ulcerative |
0.6% |
| Leukaemia |
0.6% |
| Psoriasis |
0.6% |
| Thrombocytosis |
0.6% |
|
| Renal Impairment |
11.8% |
| Skin Lesion |
8.8% |
| Weight Increased |
8.8% |
| White Blood Cell Count Decreased |
8.8% |
| Hepatic Steatosis |
5.9% |
| Liver Function Test Abnormal |
5.9% |
| Neutropenia |
5.9% |
| Pancreatitis |
5.9% |
| Varices Oesophageal |
5.9% |
| Alanine Aminotransferase Increased |
2.9% |
| Ammonia Increased |
2.9% |
| Bone Marrow Failure |
2.9% |
| Cardio-respiratory Arrest |
2.9% |
| Cyanosis |
2.9% |
| Drug Exposure During Pregnancy |
2.9% |
| Fatigue |
2.9% |
| Mucoepidermoid Carcinoma |
2.9% |
| Platelet Count Decreased |
2.9% |
| Platelet Disorder |
2.9% |
| Pneumonia Respiratory Syncytial Viral |
2.9% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
47.0% |
| Burkitt's Lymphoma |
10.9% |
| Acute Myeloid Leukaemia |
6.7% |
| Product Used For Unknown Indication |
5.4% |
| Chemotherapy |
5.2% |
| Prophylaxis |
3.7% |
| B Precursor Type Acute Leukaemia |
3.0% |
| T-cell Type Acute Leukaemia |
2.8% |
| Acute Promyelocytic Leukaemia |
2.5% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
2.3% |
| Non-hodgkin's Lymphoma |
1.6% |
| Immunosuppression |
1.6% |
| Drug Use For Unknown Indication |
1.2% |
| Heart Transplant |
1.1% |
| Ill-defined Disorder |
0.9% |
| Lymphocytic Leukaemia |
0.9% |
| Ataxia Telangiectasia |
0.8% |
| Diffuse Large B-cell Lymphoma |
0.8% |
| Acute Leukaemia |
0.7% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
0.7% |
|
| Renal Impairment |
11.5% |
| Tic |
8.2% |
| Venoocclusive Liver Disease |
8.2% |
| Chronic Myeloid Leukaemia |
7.1% |
| Glioma |
7.1% |
| Vomiting |
7.1% |
| Sepsis |
5.5% |
| Urinary Tract Infection |
5.5% |
| Hypothyroidism |
3.8% |
| Neoplasm Malignant |
3.8% |
| Neutropenia |
3.8% |
| Off Label Use |
3.8% |
| Mucoepidermoid Carcinoma |
3.3% |
| Pyrexia |
3.3% |
| Thrombocytopenia |
3.3% |
| Thymus Enlargement |
3.3% |
| Metastasis |
2.7% |
| Subclavian Vein Thrombosis |
2.7% |
| Tachycardia |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
44.4% |
| Acute Myeloid Leukaemia |
6.7% |
| Acute Promyelocytic Leukaemia |
6.7% |
| Product Used For Unknown Indication |
6.7% |
| Crohn's Disease |
3.6% |
| Heart Transplant |
3.6% |
| Pneumonia |
3.6% |
| Pain |
3.2% |
| Prophylaxis |
3.2% |
| Chemotherapy |
2.8% |
| Myeloid Leukaemia |
2.8% |
| Acute Leukaemia |
2.0% |
| B Precursor Type Acute Leukaemia |
1.6% |
| Drug Use For Unknown Indication |
1.6% |
| Immunosuppression |
1.6% |
| Psoriasis |
1.6% |
| B-cell Lymphoma |
1.2% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
1.2% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
1.2% |
| Atrial Fibrillation |
0.8% |
|
| Sepsis |
9.3% |
| Neurotoxicity |
7.0% |
| Thrombocytopenic Purpura |
7.0% |
| Tic |
7.0% |
| Urticaria |
7.0% |
| Death |
4.7% |
| Drug Ineffective |
4.7% |
| Hallucination |
4.7% |
| Leukaemia Recurrent |
4.7% |
| Low Density Lipoprotein Increased |
4.7% |
| Pulmonary Embolism |
4.7% |
| Skin Turgor Decreased |
4.7% |
| Social Avoidant Behaviour |
4.7% |
| Stomatitis |
4.7% |
| Venoocclusive Liver Disease |
4.7% |
| Viith Nerve Paralysis |
4.7% |
| White Blood Cell Count Decreased |
4.7% |
| Abdominal Pain |
2.3% |
| Abscess Drainage |
2.3% |
| Alopecia |
2.3% |
|
